Skip to main content
Premium Trial:

Request an Annual Quote

Gene Synthesis Firm Sloning Gains $6.8M in European Series E Funding

NEW YORK (GenomeWeb News) - Sloning Biotechnology said today it has raised €4.7 million ($6.8 million) in Series E venture financing from one new and several previous investors.
Sloning, based in Puchheim, Germany, plans to use the cash to commercialize its Slonomics gene synthesis business internationally and to expand its Slonomax gene mutant library product line.
The round of funding included new investor LBBW Venture Capital and existing investors HBM BioVentures, KfW Bankengruppe, and Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft.
With the investment, LBBW’s Harold Poth will become a non-executive director at Sloning.
BioConnect of Frankfurt am Main, Germany, served as financial advisor to the company in the funding round.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.